{(S)-2-Cyclohexyl-1-[(2R,4S)-4-(2-methyl-allyl)-5-oxo-tetrahydro-furan-2-yl]-ethyl}-carbamic acid tert-butyl ester | 708211-23-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酯类
• 英文名称: {(S)-2-Cyclohexyl-1-[(2R,4S)-4-(2-methyl-allyl)-5-oxo-tetrahydro-furan-2-yl]-ethyl}-carbamic acid tert-butyl ester
• CAS: 708211-23-8
• 化学式: C₂₁H₃₅NO₄
• 分子量: 365.513
• InChiKey: MTWNQBZEOCMXBE-OKZBNKHCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.75
• 重原子数：
  26.0
• 可旋转键数：
  6.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  64.63
• 氢给体数：
  1.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  {(S)-2-Cyclohexyl-1-[(2R,4S)-4-(2-methyl-allyl)-5-oxo-tetrahydro-furan-2-yl]-ethyl}-carbamic acid tert-butyl ester 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 生成 [(S)-2-Cyclohexyl-1-((2R,4S)-4-isobutyl-5-oxo-tetrahydro-furan-2-yl)-ethyl]-carbamic acid tert-butyl ester
  参考文献：
  名称：

  The discovery of structurally novel CCR1 antagonists derived from a hydroxyethylene peptide isostere template

  摘要：

  The present manuscript details the discovery and early fundamental structure-activity relationship studies, involving compound 3, a novel hydroxyethylene peptide isostere derived molecule that provides micromolar inhibition of CCL3 binding to its receptor CCR1. Initial studies established this screening hit as a legitimate lead for further medicinal chemistry optimization. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.02.020
• 作为产物：
  描述：

  3-溴-2-甲基丙烯 、 tert-butyl N-[(1S)-2-cyclohexyl-1-[(2R)-5-oxooxolan-2-yl]ethyl]carbamate 在 lithium hexamethyldisilazane 作用下， 反应 3.0h， 以29%的产率得到{(S)-2-Cyclohexyl-1-[(2R,4S)-4-(2-methyl-allyl)-5-oxo-tetrahydro-furan-2-yl]-ethyl}-carbamic acid tert-butyl ester
  参考文献：
  名称：

  The discovery of structurally novel CCR1 antagonists derived from a hydroxyethylene peptide isostere template

  摘要：

  The present manuscript details the discovery and early fundamental structure-activity relationship studies, involving compound 3, a novel hydroxyethylene peptide isostere derived molecule that provides micromolar inhibition of CCL3 binding to its receptor CCR1. Initial studies established this screening hit as a legitimate lead for further medicinal chemistry optimization. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.02.020